Resistance to therapies for infection by Plasmodium vivax - Wikidata - thesis-toulmin - TriplyDB

Resistance to therapies for infection by Plasmodium vivax

Resistance to therapies for infection by Plasmodium vivax

http://www.wikidata.org/entity/Q33481576

about

Determinants of relapse periodicity in Plasmodium vivax malaria Vivax malaria in Mauritania includes infection of a Duffy-negative individual A long neglected world malaria map: Plasmodium vivax endemicity in 2010 The international limits and population at risk of Plasmodium vivax transmission in 2009 Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria Artemisinin-based combination therapy for the treatment of uncomplicated Plasmodium vivax malaria and the prevention of relapses Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date Ethical aspects of malaria control and research Primaquine in vivax malaria: an update and review on management issues Antimalarial drug discovery - approaches and progress towards new medicines.Synthesis and Evaluation of Novel Acyclic Nucleoside Phosphonates as Inhibitors of Plasmodium falciparum and Human 6-Oxopurine Phosphoribosyltransferases Therapeutic efficacy of alternative primaquine regimens to standard treatment in preventing relapses by Plasmodium vivax: A systematic review and meta-analysis Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria Functional analysis of Plasmodium vivax dihydrofolate reductase-thymidylate synthase genes through stable transformation of Plasmodium falciparum An analytical method for assessing stage-specific drug activity in Plasmodium vivax malaria: implications for ex vivo drug susceptibility testing G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map Suppressive chemoprophylaxis invites avoidable risk of serious illness caused by Plasmodium vivax malaria A high resolution case study of a patient with recurrent Plasmodium vivax infections shows that relapses were caused by meiotic siblings.The Plasmodium vivax merozoite surface protein 3β sequence reveals contrasting parasite populations in southern and northwestern Thailand Contrasting Transmission Dynamics of Co-endemic Plasmodium vivax and P. falciparum: Implications for Malaria Control and Elimination Multiple Origins of Mutations in the mdr1 Gene--A Putative Marker of Chloroquine Resistance in P. vivax Efficacy of Chloroquine for the Treatment of Vivax malaria in Northwest Ethiopia Genetic diversity and population structure of Plasmodium vivax in Central China Emerging Plasmodium vivax resistance to chloroquine in South America: an overview Effective preparation of Plasmodium vivax field isolates for high-throughput whole genome sequencing Whole genome sequencing analysis of Plasmodium vivax using whole genome capture Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials.Severe Plasmodium vivax malaria among sudanese children at New Halfa Hospital, Eastern Sudan.Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.A review of malaria transmission dynamics in forest ecosystems Plasmodium vivax sub-patent infections after radical treatment are common in Peruvian patients: results of a 1-year prospective cohort study Malaria caused by Plasmodium vivax: recurrent, difficult to treat, disabling, and threatening to life--the infectious bite preempts these hazards Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.Identifying residual foci of Plasmodium falciparum infections for malaria elimination: the urban context of Khartoum, Sudan.Resistance to chloroquine unhinges vivax malaria therapeutics

P2860

Q17485692-8AE46158-0DF3-4306-A6D0-B6D30E4DBD2A Q21034116-AEFC9D7A-3266-4FE5-A0BC-E533852D8C3A Q21144495-BC7DF3EF-937E-48A9-B5F3-CAEABAD6CDCC Q21144525-BCE70D6D-380F-4775-B344-0F7C24991036 Q24202900-6E95391A-E40E-4AC8-BDFB-6A2CC486E03D Q24202910-6EB26007-CD0B-43BB-9221-1454D7282802 Q24235351-DC4A3CF3-3CBA-46C3-97FE-D71B9CAB4CC1 Q24236067-F12C7C27-9BE8-437E-BE54-84C7B56B0228 Q24600330-68D955DC-7A5A-4B9D-9A25-250B612E49FE Q26741307-E2D15A2C-8697-4D67-AA16-C0BBB4F04620 Q26773470-2591D162-9977-4DB5-B5FE-9F432BFAADFE Q27003856-C2ADA838-8A72-46DD-AD0F-15C0BBABA03F Q27693245-19930998-B5D3-4469-8295-55B890507C06 Q27702146-94BDB298-41F8-4631-95D8-47D482DE22D6 Q28076056-24DF87A2-75C0-4138-8E74-884B94F11548 Q28476754-DD4C72A9-2946-4473-A0C2-757D9E86AEE4 Q28478579-C4B86455-068E-444A-88C9-93880F873CB5 Q28481173-AA0CA887-3DC1-4FDC-8187-3C890F7D74B2 Q28482113-F27268B9-613D-4243-87CF-DEA7EDE7A819 Q28485156-BE51278C-8067-40B1-A760-236A599326D3 Q28488306-14810B85-2546-47C6-BE68-4B85A4AE4712 Q28539392-A75D7946-4666-495E-950F-3BF80DF8DAEB Q28545082-914A65E3-732A-49D7-900E-E002569EE557 Q28547081-BCA99E65-BD0D-486D-AA03-FA6C9711C7AB Q28550721-08A07AD5-E0A6-4540-8B85-E3FE87ED5FD3 Q28553811-435C47E6-A0B8-4CFF-A2A2-617304933E00 Q28655779-60209445-9C2B-460D-BD9E-F7CE3F2BF86F Q28655984-90DA574A-711E-4C81-B95E-74222E61593B Q30459215-1A4F25B4-0084-4BD0-B5A1-94EE6D3A9B26 Q30464966-D9B7DC8C-6805-4FED-9F04-D059FEE5C917 Q30592761-CB9FE244-D757-4F5D-A2AE-8746BD0D602B Q33402585-E36ACA78-F6DE-4290-A477-3F86AC76EC97 Q33530920-9F77BD29-D38E-4B06-8F7C-F8C3C267F996 Q33715256-E1F4667E-047A-42AE-A4A3-F0E714783DA9 Q33755273-CED168E7-F7E9-486F-B9D1-A4E56DC95852 Q33813078-0D05AB99-E3D8-40D2-89CA-81388FEFD544 Q33815207-8C417D07-414F-481C-B981-1B0BC62F666E Q33828657-7B550A95-1BAB-4167-8946-EFC9CCE4B436 Q33836815-BEAEFAFA-2A8D-4461-810D-6CB470922C5F Q33839067-5FDCEDB3-00E8-408B-A7BF-2FAF1F730F37

P2860

Resistance to therapies for infection by Plasmodium vivax

http://www.wikidata.org/entity/Q33481576

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Resistance to therapies for infection by Plasmodium vivax

@ast

Resistance to therapies for infection by Plasmodium vivax

@en

type

label

Resistance to therapies for infection by Plasmodium vivax

@ast

Resistance to therapies for infection by Plasmodium vivax

@en

prefLabel

Resistance to therapies for infection by Plasmodium vivax

@ast

Resistance to therapies for infection by Plasmodium vivax

@en

P1433

Q33481576-3071D98E-D291-4D44-BDC5-C17AF7BDFD48

P1476

Q33481576-DA23016C-53BA-44BA-BEA1-EC19872958A9

P2860

Q33481576-005AAFA7-D10D-41C0-A5E7-07FB17967B2E

Q33481576-0144D872-1758-411E-B1D5-0967BA7A10DA

Q33481576-02119EAC-004E-4199-BAB8-2BF1744055BA

Q33481576-0492D38C-5A79-4758-8E3D-7FB8E62BAAC0

Q33481576-0BF98349-69AA-487F-A41B-215D2272A4EE

Q33481576-0C00896C-FCB1-47E4-8B69-01E466CB3283

Q33481576-0D3B8D31-625D-4670-A37C-674203AB47E2

Q33481576-0D8C034C-62C7-4296-9253-CC5B6C56B587

Q33481576-0E778182-9D1B-4F02-A206-0C923896C2D3

Q33481576-0EC77AD8-4C37-48B6-AC7D-59C726C74063

P304

Q33481576-77E8D99C-CC8E-4871-AEF5-840BD3A4CED2

P31

Q33481576-E0EF222D-B315-449F-A609-15A285B16174

P356

Q33481576-82DA2BDA-C4C1-4256-9E0E-F4D8F05FAA8F

P407

Q33481576-97096139-23A3-4E60-9F85-CD3537DB6631

P433

Q33481576-686694B7-7915-4080-868C-FCDB28B7BB86

P478

Q33481576-C221E740-2F9A-4470-850B-9AB8C7812C26

P50

Q33481576-D30D2B3F-7971-4B09-8812-DB16DD1ACBAB

P577

Q33481576-A06FF574-84D9-4279-96B6-EF44D1AF4D05

P698

Q33481576-09905D10-7BC6-43F7-9592-D87BEF442D92

P921

Q33481576-6EB0E955-6BEC-4313-B24E-8089ED77FEAD

P932

Q33481576-21BFDEDA-8DA8-48D4-B8E6-FAC1DFE70118

P356

P1433

Clinical Microbiology Reviews

P1476

Resistance to therapies for infection by Plasmodium vivax

@en

P2860

The evolution of tafenoquine--antimalarial for a new millennium?

Therapeutic responses to different antimalarial drugs in vivax malaria

Failure to detect Plasmodium vivax in West and Central Africa by PCR species typing

Population genetic structure of Plasmodium falciparum in the two main African vectors, Anopheles gambiae and Anopheles funestus

Malaria in American troops in the South and Southwest Pacific in World War II

Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop

Clustered local transmission and asymptomatic Plasmodium falciparum and Plasmodium vivax malaria infections in a recently emerged, hypoendemic Peruvian Amazon community

A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria

Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia

Short report: the activity of pamaquine, an 8-aminoquinoline drug, against sporozoite-induced infections of Plasmodium vivax (New Guinea strains)

P304

508-534

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/CMR.00008-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19597012

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium vivax

P932

2708388

http://www.w3.org/2001/XMLSchema#string